Pharming Group N.V.
PHAR
$8.00
-$0.6233-7.23%
| 06/30/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | ||
|---|---|---|---|---|---|
| Revenue | 74.09M | 81.22M | 66.66M | 54.90M | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | 74.09M | 81.22M | 66.66M | 54.90M | |
| Cost of Revenue | 7.98M | 7.12M | 8.30M | 5.72M | |
| Gross Profit | 66.11M | 74.10M | 58.37M | 49.17M | |
| SG&A Expenses | 48.55M | 57.28M | 36.01M | 44.89M | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -912.00K | 20.74M | -304.00K | -848.00K | |
| Total Operating Expenses | 77.21M | 96.51M | 64.75M | 70.68M | |
| Operating Income | -3.12M | -15.29M | 1.91M | -15.78M | |
| Income Before Tax | -60.00K | -2.03M | 3.31M | 3.39M | |
| Income Tax Expenses | 1.16M | 1.09M | -157.00K | 2.07M | |
| Earnings from Continuing Operations | -1.22M | -3.12M | 3.46M | 1.32M | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -1.22M | -3.12M | 3.46M | 1.32M | |
| EBIT | -3.12M | -15.29M | 1.91M | -15.78M | |
| EBITDA | -1.17M | -7.74M | 4.81M | -14.43M | |
| EPS Basic | 0.00 | 0.00 | 0.01 | 0.00 | |
| Normalized Basic EPS | 0.00 | -0.02 | -- | -0.02 | |
| EPS Diluted | 0.00 | 0.00 | 0.01 | 0.00 | |
| Normalized Diluted EPS | 0.00 | -0.02 | -- | -0.02 | |
| Average Basic Shares Outstanding | 688.98M | 675.00M | 692.80M | 672.01M | |
| Average Diluted Shares Outstanding | 688.98M | 675.00M | 692.80M | 672.01M | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |
